Delhi High Court Allows Zydus Lifesciences to Make Biosimilar Nivolumab
Delhi High Court permitted Zydus Lifesciences to manufacture and sell a biosimilar of Nivolumab, a monoclonal antibody immunotherapy drug. Nivolumab enhances immune response by blocking the PD-1 receptor, enabling recognition and destruction of cancer cells. Monoclonal antibodies are lab-produced molecules for targeted action. Used for lung, renal, head and neck, melanoma, urothelial, oesophageal and gastric cancers; adult dosing 240 mg biweekly or 480 mg every 4 weeks. Brands: Opdivo (outside India), Opdyta (India).




